Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bois-Guillaume – page 26

671 clinical trials in Bois-Guillaume, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bois-Guillaume at a glance
671
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

671 trials in Bois-Guillaume

Open in trial search

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Not yet recruiting

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Alopecia areata

Not yet recruiting

Study of ritlecitinib tosilate for hair regrowth in adults and adolescents (12 years and older) with moderate alopecia areata

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Acne

Not yet recruiting

Low-dose isotretinoin compared with drug combination for treating acne in adult women: a two‑step randomized trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adapalene
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Renal transplant+1

Not yet recruiting

Effect of Continuing Tacrolimus on Access to a Second Kidney Transplant in Patients with Renal Transplant Failure: A Randomized Controlled Trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:University Hospital Of Clermont-Ferrand

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Pulmonary arterial hypertension

Not yet recruiting

Phase 2 Randomized Trial of Oral NS-863 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Septic shock

Not yet recruiting

Efficacy of dapagliflozin in adult patients with septic shock and microcirculatory dysfunction

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Bois-Guillaume

What the registry says about research in the country

01 Kidney Disease & Transplantation

Innovative research focusing on chronic kidney disease treatments and transplant outcomes, including studies of novel medications like baxdrostat and tegoprubart for improving patient care.

  • Kidney Transplant Rejection Prevention
  • CKD Management
  • Hypertension Control

Multiple trials evaluating new therapeutic approaches for transplant recipients and CKD patients.

02 Blood Disorders

Clinical investigations into treatments for various blood-related conditions, with emphasis on immune thrombocytopenia and thrombotic disorders.

  • Thrombotic Thrombocytopenic Purpura
  • Hemolytic Uremic Syndrome
  • Immunological Therapies

Advanced studies combining established and experimental treatments for better patient outcomes.

03 Infectious Disease Management

Research examining treatment strategies for viral infections and optimization of antibiotic therapy, particularly in elderly populations.

  • Cytomegalovirus Treatment
  • Antibiotic Management
  • Viral Pneumonia

Studies focused on improving treatment protocols and reducing antibiotic overuse.

04 Autoimmune Conditions

Investigation of novel therapies for vasculitis and related autoimmune disorders, including targeted biological treatments.

  • Takayasu Arteritis
  • ANCA-Associated Vasculitis
  • Goodpasture Disease

Evaluating new treatment combinations to improve disease management and patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.